Becton, Dickinson and Company BDX, popularly known as BD, recently announced the expansion of its partnership with Ypsomed to develop a 5.5 mL version of the BD Neopak XtraFlow Glass Prefillable Syringe. BD and Ypsomed have a long-standing partnership that began with the BD Neopak XtraFlow 2.25 mL Glass Prefillable Syringe and the YpsoMate 2.25 autoinjector that delivered improved flow and faster injection times across multiple drug viscosities.
The new 5.5 mL version builds on this progress, and it is designed for full compatibility with Ypsomed’s YpsoMate 5.5 autoinjector. The expanded partnership aims to address the growing demand for large-volume subcutaneous self-injection required by pharmaceutical companies and patients.
Per management, the next-generation syringe is developed to meet the rising demand for easy-to-use solutions for high-dose biologic medicines. By bringing together BD’s experience in drug delivery and Ypsomed’s expertise in autoinjector technology, the companies aim to make self-injection simpler and more convenient for patients living with complex health conditions. Both companies are working closely with pharmaceutical partners to expand subcutaneous drug delivery options for high-dose therapies, including higher volumes and thicker formulations.
Following the announcement, shares of BDX gained 1.4% at yesterday’s closing. Over the past six months, shares of the company have climbed 13.7% compared with the industry’s 13.9% growth and the S&P 500’s 10.4% rise.
In the long run, the expanded partnership with Ypsomed enhances BD’s competitive positioning in drug delivery systems by aligning its prefillable syringe technology with a leading autoinjector platform. As biologics pipelines shift toward higher-dose, subcutaneous formulations, BD stands to benefit from increased adoption of its Neopak XtraFlow platform and deeper engagement with pharmaceutical customers. Availability of syringe samples for studies in mid-2026 provides BD with a multi-year runway to capture growth from the expanding biologics market while strengthening its role as a preferred drug-delivery partner for high-dose therapies.
BDX currently has a market capitalization of $57.95 billion.
Image Source: Zacks Investment Research
The new 5.5 mL BD Neopak XtraFlow Glass Prefillable Syringe incorporates BD’s advanced technology, such as a shorter 8-millimeter needle and thinner cannula walls, to better deliver medicines with higher volumes and thicker formulations. These features help improve flow and reduce injection time, overcoming common issues with large-volume biologics and allowing drug developers to go beyond the limits of standard syringes.
link
